Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration

Olga Pitsillidou, Panagiotis Petrou, M. J. Postma

Open source

DOI
10.1080/14737167.2026.2717293
Published
2026-08-23
Container
Expert Review of Pharmacoeconomics & Outcomes Research
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14737167.2026.2717293,
  title = {Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration},
  author = {Olga Pitsillidou and Panagiotis Petrou and M. J. Postma},
  year = {2026},
  journal = {Expert Review of Pharmacoeconomics \& Outcomes Research},
  doi = {10.1080/14737167.2026.2717293},
  url = {https://doi.org/10.1080/14737167.2026.2717293}
}

RIS

TY  - JOUR
TI  - Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration
AU  - Olga Pitsillidou
AU  - Panagiotis Petrou
AU  - M. J. Postma
PY  - 2026
JO  - Expert Review of Pharmacoeconomics & Outcomes Research
DO  - 10.1080/14737167.2026.2717293
UR  - https://doi.org/10.1080/14737167.2026.2717293
ER  - 

APA

Pitsillidou, O., Petrou, P., & Postma, M. J. (2026). Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2717293

Source records